ImmunityBio, Inc. (IBRX): R&D Expense
$190.14M
Year ended 2024-12-31
-1.0%
3-year compound annual growth
+11.2%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $190.14M | -18.2% | 2025-03-03, From 2024-01-01 |
| 2023-12-31 | $232.37M | -6.4% | 2025-03-03, From 2023-01-01 |
| 2022-12-31 | $248.15M | +26.6% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $195.96M | +40.5% | 2024-03-19, From 2021-01-01 |
| 2020-12-31 | $139.51M | +24.6% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $112.00M | +101.0% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $55.72M | +32.5% | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $42.04M | +44.2% | 2020-03-25, From 2017-01-01 |
| 2016-12-31 | $29.15M | +155.0% | 2019-03-13, From 2016-01-01 |
| 2015-12-31 | $11.43M | +616.9% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $1.59M | +257.6% | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | $446.0K | n/a | 2016-03-30, From 2013-01-01 |